FNY Investment Advisers’s Cidara Therapeutics CDTX Stock Holding History

FNY Investment Advisers’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-145,533	Closed	-$32.1M	–	815
2025 Q4	$32.1M	Buy	+145,533	New	+$23.5M	9.07%	1
2024 Q2	–	Sell	-2,830	Closed	-$52	–	486
2024 Q1	$52	Buy	+2,830	New	+$40.6K	0.03%	258

FNY Investment Advisers's CDTX Position: Q1 2026 in Review

FNY Investment Advisers sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 145,533 shares — an estimated $32.1M sold.

FNY Investment Advisers first reported a position in CDTX in Q1 2024 and held it in 2 quarters. The position peaked at $32.1M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

FNY Investment Advisers reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
FNY Investment Advisers sold 145,533 Cidara Therapeutics shares in Q1 2026, an estimated $32.1M.
FNY Investment Advisers first reported a position in Cidara Therapeutics in Q1 2024 and held it in 2 quarters.
FNY Investment Advisers's Cidara Therapeutics position peaked at $32.1M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on FNY Investment Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.